The nation of Zimbabwe has rejected a significant American health deal valued at $367m (£272m) over five years due to the United States' demand for sensitive data.
This rejection became public following a official document dated December was leaked, revealing that Head of State Emmerson Mnangagwa deemed the arrangement was "lopsided".
A government spokesman has since stated that the US was requesting genetic material for scientific study and commercial purposes but was unwilling to share the resulting advantages from any future vaccines.
"We are forced to start the challenging and unfortunate process of ending our support in Zimbabwe," remarked US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had provided more than $1.9bn in health funding to Zimbabwe over the last twenty years.
A medical body in Zimbabwe has appealed for continued talks to reach a deal agreeable to both sides so the country's vital HIV programme can continue.
Wider Background
Zimbabwe's decision comes after a similar case in Kenya, where a high court halted a related deal with the US following legal challenges were filed about the safety of citizens' medical information.
After resuming the presidency last year, US President Donald Trump has reduced overseas assistance and shut down the US Agency for International Development (USAID).
The agency had administered aid for the US government, but Trump claimed its spending was "wasteful" and his administration was pursuing government-to-government deals to boost openness and responsibility.
As per statements, 16 nations in Africa have so far agreed to these new health pacts, constituting over $18.3bn of fresh investment.
Details of the Declined Deal
The money for Zimbabwe was intended to gone towards "combating HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We believe this collaboration could have provided significant advantages for Zimbabwean communities, especially the 1.2 million men, women and children presently receiving antiretroviral therapy via American-funded programmes," the Ambassador said.
However, government spokesperson Nick Mangwana argued the arrangement was "unequal".
"Zimbabwe was being asked to provide its genetic material and health information over an extended period, with no equivalent promise of access to any scientific breakthroughs – like new medicines or tests – that could result from that provided information," his statement read.
"Effectively, our nation would provide the basic resources for scientific discovery with no certainty that the final treatments would be available to our people if a future disease outbreak arise."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its pursuit of one-on-one health agreements were upending systems previously established through the international organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing scheme designed to deal with future global health emergencies.
"This framework is designed to guarantee that when a nation provides its samples, the resulting advantages – such as medicines and cures – are shared equitably, not monopolised solely by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as opposition to America," he added.
"We encourage further dialogue with our US partners on how subsequent co-operation could be arranged in a manner that respects the sovereignty and dignity of both nations."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) expressed it recognised the official position, but suggested that talks must proceed considering much of the country's Aids initiatives depended on international support.
"If technical issues exist, such as those involving data governance or implementation frameworks, these can often be resolved via detailed discussion and negotiated safeguards," it commented.
The halted deal underscores the ongoing challenges between receiving vital foreign assistance and protecting a country's data in an increasingly data-driven world.